Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy
Comparison of Continuous Subcutaneous Insulin Infusion (CSII) With Multiple Daily Injections (MDI) for the Treatment of Pregestational Diabetes During Pregnancy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3T 0G9
- Jim Pattison Outpatient Care and Surgery Centre
-
Vancouver, British Columbia, Canada
- B.C. Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- subjects are attending the Diabetes Pregnancy Clinic at participating hospitals
- have had type 1 or type 2 diabetes for at least one year
- are in the first trimester or are actively attempting pregnancy
- have a singleton pregnancy
- are receiving intensive insulin therapy
- are judged by clinic staff to be capable of using an insulin pump
- are age 19 or older
- are willing to adhere to the study protocol including monitoring blood glucose levels
- are willing to take folic acid before pregnancy and during the first trimester
- are willing to discontinue any medication contraindicated in pregnancy prior to conception
- weigh less than 100 kg (220 lb) prior to becoming pregnant
- use less than 100 units of insulin per day
Exclusion Criteria:
- current or previous use of an insulin pump
- use of fertility treatments
- have a multiple pregnancy
- have had children born with major birth defects
- have experienced stillbirth or multiple early pregnancy losses
- have significant diabetes complications or a serious medical issue
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: insulin pump
subjects will use an insulin pump for the duration of the pregnancy.
The intervention is that they will control their diabetes using an insulin pump
|
subjects in the experimental arm will administer insulin using a pump
|
|
Active Comparator: Multiple Daily Insulin injections
subjects will continue their usual insulin treatment with multiple daily injections of sc insulin
|
Subjects will continue with usual insulin injections
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite obstetrical/perinatal endpoint consisting of specific elements (see description)
Time Frame: Up to 42 weeks
|
Composite obstetrical/perinatal endpoint consisting of one or more of pre-eclampsia, primary caesarian section, pre-term delivery, spontaneous abortion, termination for congenital anomaly or chromosomal abnormality, perinatal mortality, large-for-gestational age, shoulder dystocia, birth injury, major congenital anomaly, neonatal hypoglycemia, jaundice requiring phototherapy, or admission to neonatal intensive care nursery.
|
Up to 42 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean maternal HbA1c during pregnancy
Time Frame: up to 42 weeks
|
HbA1c will be measured at least every three months to provide information about overall glycemic control
|
up to 42 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of episodes of severe hypoglycemia
Time Frame: up to 42 weeks
|
Severe hypoglycemia is defined as capillary glucose < 3.3 mmol/L requiring the assistance of another person for treatment.
|
up to 42 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: David M Thompson, MD, University of British Columbia
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Pregnancy Complications
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Type 1
- Diabetes, Gestational
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Insulin
- Insulin, Globin Zinc
Other Study ID Numbers
Other Study ID Numbers
- H12-02375
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.